Platelet-derived growth factor receptor (PDGFR)a expression was found in ovarian cancer cells and tumors by microarray hybridization. This led us to test whether ovarian cancers also produce ligands for this receptor, as this would demonstrate that such malignancies support their own growth and spread through autocrine activation. We assayed the expression of ligands for the PDGFR in ovarian tumors, cell lines and peritoneal fluid using RT-PCR, immunohistochemistry (IHC) and ELISA. We detected strong mRNA expression for the PDGFRa ligands in most ovarian tumors. Receptor and ligand expressions (PDGFRa and PDGF AB) were also detected by IHC in, respectively, 34 and 32 of 47 ovarian tumors. The stainings for PDGFRa and PDGF AB were strongly correlated (P-value ¼ 0.014), suggesting that an autocrine loop is functional in ovarian cancer. PDGF AA and BB were quantified in peritoneal fluid by ELISA. Both ligands are secreted at higher levels in ovarian cancer ascites specimens (n ¼ 54) than in fluid from nonmalignant disorders (n ¼ 8). PDGF was detected in media conditioned by ovarian cancer cells. Such conditioned media induced activation of the PDGFR, Akt and MAPK and stimulated cell proliferation. A neutralizing PDGF antibody blocked these effects. Specific PDGFR inhibition by siRNA or a neutralizing antibody to the receptor inhibited PDGF-stimulated receptor activation and cell proliferation, suggesting that receptor targeting has a role in ovarian cancer treatment.
Introduction
Epithelial ovarian cancer (EOC) is the leading cause of mortality among gynecological malignancies and the fifth leading cause of cancer-related death in women (Greenlee et al., 2000) . Treatment for ovarian cancer relies on surgical debulking and platinumbased chemotherapy. However, most patients relapse and chemotherapy offers limited, temporary benefit (Ozols, 1997) , with response rates for nonplatinumbased chemotherapy regimens ranging from 10 to 20% (Gordon et al., 2001) . Novel agents are being tested in women with ovarian cancer, with emphasis on targeting biological mechanisms important to tumor expansion (Bookman et al., 2003) . Some of these strategies involve targeting growth factor receptors thought to be important in the development and growth of ovarian tumors (such as epidermal growth factor receptor, Her 2 neu, platelet derived growth factor receptor, etc.). Further understanding of the role played by various growth factor receptors, and the growth pathways they activate, is important for developing effective therapies for ovarian cancer.
The platelet-derived growth factor receptors (PDGFR) (a and b) are transmembrane receptor tyrosine kinases activated by PDGF (Hart et al., 1988; Matsui et al., 1989; Eriksson et al., 1992) . They are implicated in a variety of physiologic and pathologic processes, including cell growth and survival (Yao and Cooper, 1995) , transformation (Huang et al., 1984) , migration (Uren et al., 1994; Yu et al., 2001) , vascular permeability, stroma modulation and wound healing (Greenhalgh et al., 1990) . PDGF binds selectively to receptor subunits, based on specific epitopes (Jensen et al., 1992; Yu et al., 1994) ; PDGF AA binds the PDGFRa, whereas PDGF AB and BB recognize both the PDGFRa and b (Hart et al., 1988) . Two recently cloned forms of PDGF, PDGF C and D (Li et al., 2000; LaRochelle et al., 2001; Aase et al., 2002; Lokker et al., 2002) , with similar mitogenic properties (Zwerner and May, 2001) , bind PDGFRa and b, respectively. In cell culture systems, PDGFR activation promotes its interaction with and activation of proteins with SH2 domains, including phosphoinositol 3-kinase (PI3K), phospholipase gC (Valius and Kazlauskas, 1993) , GTPase activating protein, Src family tyrosine kinases, as well as Shc, Nck, Grb, Crk and STATs (Heldin et al., 1998) . The two PDGFRs mediate similar, but not identical processes, some differences being cell-type specific.
Several groups, including ours, reported expression of the PDGFR in ovarian tumors (Henriksen et al., 1993; Schmandt et al., 2003; Matei et al., 2004) . PDGFRa, but not b, is differentially expressed in ovarian carcinoma compared to normal ovarian epithelium. Furthermore, in a limited number of cases, expression of PDGFRa was linked to poor prognosis (Henriksen et al., 1993) and high expression of the receptor correlated with aggressive tumor characteristics (high proliferation index and high histologic grade) (Lassus et al., 2004) . Recently, the PDGFR emerged as part of a molecular signature defining unfavorable clinical outcome in patients with EOC (Spentzos et al., 2004) . While these reports suggest a potential role for the PDGFR in the growth of ovarian tumors, it has not been clearly demonstrated whether and how the receptor is activated in this malignancy. Recent studies scanning for PDGFRa mutations did not find activating mutations of the receptor in ovarian tumors (Lassus et al., 2004; Sihto et al., 2005) . A previous report suggested that PDGF, the natural ligand of the receptor, is present at the mRNA level in ovarian cancer cell lines, suggesting that an autocrine or paracrine loop might be functional in EOC (Versnel et al., 1994) ; however, expression of the protein was not demonstrated in tumors and, more importantly, not identified in primary tumor cells.
Here, we report that the PDGFRa is highly expressed in ovarian tumors. Its ligands are detected at the mRNA and protein levels in ovarian tumors and PDGF is secreted in ascites fluid in patients with ovarian cancer. The receptor and its downstream substrates are activated in ovarian cancer cells and such activation is blocked by siRNA and a neutralizing PDGFRa antibody. Thus, an autocrine mechanism appears to be functional in ovarian tumors and PDGFRa targeting significantly blocks ovarian cell proliferation.
Results

PDGFR and PDGF expression in ovarian tumors
PDGFRa and b were detected at the mRNA level in most ovarian tumors tested (Figure 1a) . Likewise, PDGF A and C, ligands for the PDGFRa, and PDGF D, ligand for PDGFRb, are present in most ovarian tumors. However, PDGF B was detected in only two of 12 ovarian tumors (Figure 1b and c) . These data suggest that the PDGF receptors and their ligands are expressed in the majority of ovarian tumors.
We then examined receptor and ligand expression at the protein level, utilizing IHC, and found PDGFRa in 34 of 47 ovarian tumors. Among 23 serous papillary ovarian tumors, 13 (56%) expressed the PDGFRa (Figure 2 ). The normal surface ovarian epithelium did not immunoreact in five of six specimens. However, we noted PDGFRa immunostaining in ovarian epithelial invaginations (1 þ staining in three specimens and 2 þ staining in one case) as well as in the epithelium of fallopian tubes (1 þ staining in one case and 2-3 þ staining in four specimens), at levels comparable to that of ovarian carcinomas. This suggests that the PDGFR pathway may be important not only to carcinogenesis but also to metaplastic transformation of the mullerian epithelium.
In a preliminary analysis, we noted strong PDGFRa expression in clear cell carcinomas, leading us to focus on this histological subtype. Significant (2-3 þ ) membranous immunoreactivity was observed in 17 of 19 clear cell tumors, suggesting that PDGFRa is a potential target in this subgroup of tumors, which are characterized by poor clinical outcome and chemoresistance (Ikeda et al., 2003) . The results of IHC are summarized in Table 1. IHC confirmed PDGF AB staining in most ovarian tumors, strong PDGF immunoreactivity (2-3 þ ) being observed in the cytoplasm of tumor cells in 32 of 47 specimens (67%). Of the 19 clear cell tumors, 18 stained for PDGF AB. Occasionally, secretory granules of PDGF immunoreactive material were identified in tumor (Figure 2 ). Other cells in the stroma (especially fibroblasts and endothelial cells) immunoreacted with PDGF AB. Normal ovarian epithelium stained strongly (2 þ ) for PDGF AB in three of six specimens, and weak (1 þ ) expression was recorded in two additional samples, suggesting that PDGF AB expression is not cancer-specific.
Among ovarian tumor samples, there was a statistically significant association of high expression (2-3 þ ) for PDGF AB and PDGFRa (n ¼ 47, P-value ¼ 0.014, Fisher's exact test). Receptor and ligand coexpression in tumor cells indicates that an autocrine mechanism is operative in EOC.
PDGF secretion in ascites fluid EOC is characterized by increased permeability of the peritoneal lining, leading to accumulation of peritoneal fluid. This fluid provides a medium for dissemination of malignant cells along the peritoneum and contains mediators of inflammation, as well as secreted proteins from tumor or stromal cells. Quantification of PDGFs in this fluid would show whether these growth factors are secreted in the peritoneal cavity, where they would stimulate tumor cell growth and spread. PDGF AA was quantifiable in 36/54 samples (values over 150 pg/ml) and PDGF BB was measurable in 26/54 samples (values over 50 pg/ml). The median level of PDGF AA was 527.7 pg/ml in cancer samples (range 0-54 052 pg/ml) and that of PDGF BB was 45 pg/ml (range 0-1227 pg/ ml). As control, PDGFs were measured in pleural fluid from patients with inflammatory diseases (n ¼ 8). Three of eight non-cancer-related pleural fluid specimens contained PDGF AA>150 pg/ml and two samples contained PDGF BB>50 pg/ml, and the rest of the specimens did not contain quantifiable PDGF. Several samples of ascites fluid contained very high levels of PDGF, all but one being malignant cases. Measurable levels of PDGF were not predictive of a diagnosis of ovarian malignancy; however, higher concentrations of both ligands, but more so of PDGF AA, were detected in cancer than in nonmalignant specimens ( Figure 3 and Table 2 ).
PDGFRa activation in cancer cells
To test whether the PDGF-PDGFR system is activated in ovarian cancer cells, we evaluated whether serum-free medium conditioned by such cells would induce receptor phosphorylation, activate downstream signaling pathways important for growth and survival, and promote cell proliferation. We then tested whether a neutralizing PDGF antibody would inhibit these effects. Several cell lines were screened for the presence of the PDGF receptor, which would then be tested for activation by conditioned medium. PDGFRa and b were detected by Western blotting in primary cultures derived from ovarian tumors (C908, C848) and in immortalized primary tumor cultures (C272-hTERT/E7), but not in the CaOv3 and OV90 cancer cell lines (weak expression of PDGFRa was recorded in OV90). The receptor was not identified in primary cells from normal ovarian epithelium (HOSE) or in immortalized primary cells from normal epithelium (H281-hTert/E7; Figure 4 ). c-kit, a related transmembrane receptor, was not detected in any of the cell lines tested.
The results from the experiments described in Figure 4 led us to test whether the medium conditioned by immortalized cells induces receptor phosphorylation comparable to that induced by PDGF in C272/hTert/ E7 cells. Serum-free conditioned medium induced receptor phosphorylation similar to activation by 5 ng/ml of PDGF BB (Figure 5a ) in these cells. Preincubation of the conditioned medium with the neutralizing PDGF AB antibody inhibited receptor phosphorylation ( Figure 5b ).
Conditioned medium also activated MAPK and Akt in C272/hTert/E7 cells, as assayed by antibodies to phospho (active) Akt and phospho (active) MAPK ( Figure 5b ). Preincubation of the conditioned medium with the neutralizing PDGF AB antibody blocked activation of these effector proteins.
Conditioned medium stimulated proliferation of C272-hTert/E7 cells, as assayed by BRDU incorporation. Preincubation of the conditioned medium with the neutralizing PDGF AB antibody inhibited cell proliferation fueled by conditioned media (Figure 5c ).
To definitively identify the ligand that activates the PDGFR in conditioned medium, we immunoblotted, under reducing conditions, equal amounts of serum-free medium collected from ovarian cancer cells. We detected a band immunoreactive with the PDGF AB antibody in Figure 3 Results of ELISA for PDGF AA and BB in peritoneal fluid. In total, 54 ascites specimens from ovarian cancer patients and eight specimens from pleural inflammatory disorders were included in the analysis. The graphs illustrate box plots and whisker of PDGF AA and BB by group (cancer versus noncancer). The shaded region encloses the data between the first and third quartiles. The line in the box denotes the median. The whisker is the area above the third quartile times 1.5 the interquartile range (weight of the box). (Figure 5d ).
Peritoneal fluid induces PDGFRa activation
To prove activation of the PDGF/PDGFR system in vivo in ovarian cancer, we cultured primary cells from ascites fluid. The cell culture tested here, OVCA2, expresses PDGFRa (Figure 6a ). After expansion (two passages), cells were starved overnight and stimulated with preserved ascites fluid and receptor activation was assayed. Peritoneal fluid stimulated PDGFR phosphorylation and activation of Akt and MAPK. Preincubation of the ascites fluid with the neutralizing PDGF AB antibody inhibited PDGFRa activation and activation of Akt and MAPK (Figure 6b ), suggesting that the receptor is stimulated in vivo by a ligand secreted from tumor cells or stroma into the surrounding peritoneal fluid.
PDGFR inhibition blocks cell proliferation
We used siRNA and a neutralizing antibody for PDGFRa to test the significance of the PDGFRa in ovarian cancer cells. Receptor downregulation was induced by siRNA duplex concentrations greater than 25 nM (Smart pool, Dharmacon; Figure 7a ) and downregulation was maintained for 48-96 h (Figure 7b ). In the presence of siRNA targeting the PDGFRa, PDGFstimulated cell proliferation was blocked compared to siRNA control (Figure 7c ). PDGF AA-induced proliferation was affected to a greater extent than cell growth stimulated by PDGF BB (P-value ¼ 0.05). This effect is due to preserved signaling through PDGFRb, as PDGF BB can activate both receptors, while PDGF AA binds specifically to the a receptor. We utilized a fully human receptor-neutralizing antibody (3G3) and assayed receptor activation and cell proliferation induced by PDGF. Rituximab, a humanized anti-CD20 antibody, was used as a control. In the presence of the PDGFRa neutralizing antibody 3G3, PDGF AA induced receptor phosphorylation, and activation of downstream signaling substrates, Akt and MAPK, was fully inhibited (Figure 8a) . However, the neutralizing antibody did not inhibit PDGF BB-stimulated receptor phosphorylation and activation of Akt and MAPK (Figure 8b ). The anti-PDGFRa antibody blocked significantly PDGF AA-stimulated 
Discussion
The present study shows that PDGFRa is expressed in a cancer-specific manner in ovarian tumors. (c) Cell proliferation measured as BRDU incorporation is quantified in C272Hter/E7 cells treated with siRNA for PDGFRa (100 nM) or siRNA control 18 h after stimulation with PDGF AA (25 ng/ml) or BB (25 ng/ml). PDGF AA-induced cell proliferation is significantly inhibited in the presence of siRNA for PDGFRa compared to siRNA for control (P-value ¼ 0.05).
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, but the functional significance of the receptor to cancer progression has not been demonstrated. In other malignancies, constitutive activation of PDGFRa can occur as a consequence of activating mutations (as in gastrointestinal stromal tumors (GIST); Heinrich et al., 2003) . To date, such mutations have not been described in ovarian tumors (Lassus et al., 2004; Sihto et al., 2005; Wilczynski et al., 2005) . In the tumor milieu, the receptor can be activated by ligands secreted from tumor or stromal cells. Autocrine or paracrine engagement of the receptor can activate signaling pathways promoting cell proliferation and survival processes, essential to tumor expansion. The data presented here strongly suggest that an autocrine loop fuels ovarian cancer cell proliferation. Aside from proliferation, the activated receptor modulates other processes significant to tumor expansion (migration (Yu et al., 2001) , invasion, stroma modulation (Franklin et al., 1990; Pietras et al., 2002; Dong et al., 2004) , etc.); however, these effects were not examined in the current report.
While our studies focus on PDGFRa, the b receptor may also play a role in tumor expansion and growth. A previous report showed PDGFRb expression in the majority of serous ovarian tumors, albeit no differential expression was found between normal epithelium and malignant cells (Schmandt et al., 2003) .
In this study, we demonstrate that PDGFRa is strongly expressed in tumors and that its expression correlates with immunoreactivity for PDGF AB (Pvalue ¼ 0.014). We show that PDGF A and C, specific ligands for the a receptor, are expressed in the majority of serous ovarian tumors tested. Similarly, PDGF AA is secreted in the majority of ascites fluid specimens from patients with ovarian cancer. Interestingly, PDGF BB, ligand for both a and b receptors, is expressed only weakly in two tumor samples and PDGF BB is secreted at lower levels in peritoneal fluid. These results suggest that activation of the a receptor may be more important to ovarian tumor expansion than the b receptor.
An important observation of this study is that PDGFRa is strongly expressed (2-3 þ ) in clear cell carcinomas (17 of 19 specimens). PDGF AB is also strongly expressed in these tumors (18 of 19 tumors). This implicates a PDGF-activated mechanism in the growth of clear cell carcinomas, and suggests that therapeutic targeting of the receptor should be explored in this chemo-resistant subset of tumors.
We found PDGF in peritoneal fluid in most cancer specimens. Several samples contained PDGF AA at very high levels (over 2000 pg/ml). We believe that PDGF is produced by tumor or stromal cells and modulates permeability of the peritoneal lining and shaping of the onco-matrix, facilitating tumor survival and spread. This is the first report documenting increased levels of these growth factors in ascites fluid. We noted that, respectively, two and three of the nonmalignant (inflammatory) specimens contain detectable amounts of PDGF BB and AA. This suggests that secretion of ligands may accompany non-neoplastic processes, PDGFs being important for stroma modulation and vascular permeability (Dong et al., 2004) , which could be altered in the context of inflammation.
Using immortalized primary cells, we demonstrate that PDGFR is activated by ligand secreted from tumor cells and that endogenous PDGFR activation fuels cell proliferation and activation of downstream targets Akt and MAPK through an autocrine process. Utilizing a model resembling the intraperitoneal milieu (cells cultured from ascites fluid, stimulated with peritoneal fluid), we also show strong activation of the receptor and downstream substrates by the ascites fluid. An anti-PDGF antibody inhibits receptor activation. These data provide strong evidence that the receptor is active in ovarian tumors.
While our data with cells stimulated with ascites demonstrate an operative autocrine mechanism in ovarian cancer, the studies with ascites fluid do not exclude paracrine engagement of the PDGFR. The composition of ascites fluid is regulated by mesothelial and stromal cells, as well as by tumor elements. Thus, the presence of PDGF in ascites fluid reflects secretion from both malignant and stromal cells.
Specific blocking of receptor function using siRNA or receptor-neutralizing antibody inhibits cell proliferation (Figures 7 and 8) . Interestingly, the neutralizing antibody to PDGFRa blocked the action of PDGF AA, but not that of PDGF BB. PDGF AA is a specific PDGFRa ligand, while PDGF BB activates both receptors a and b. Preserved signaling through PDGFRb, which is expressed in these cells and is not affected by the neutralizing antibody, explains the effects noted.
These data are consistent with our previous results demonstrating that a tyrosine kinase inhibitor (Imatinib mesylate) inhibits ovarian cancer cell proliferation and PDGF-induced S-phase entry (Matei et al., 2004) , but further narrows to the function of the receptor by using modalities of PDGFR inhibition, which are more specific. The data presented here provide a strong experimental rationale for moving forward clinical investigations aimed at PDGFR inhibition, by utilizing receptor tyrosine kinase inhibitors or antibody-based therapy. Such studies are currently under way for patients with ovarian cancer.
Materials and methods
RT-PCR
RNA was extracted from snap-frozen specimens (12 serous papillary tumors from the Cedars Sinai Tissue Bank) using RNA STAT 60 reagent (Tel-Test Inc., Friendswood, TX, USA). RNA (1 mg) was utilized for first-strand cDNA synthesis using the Superscript II system (Invitrogen, Carlsbad, CA, USA). For the PCR reactions, the following primers were utilized (Lokker et al., 2002) CAG AGG TCT GCG AG (F), CAC TCT CTT CAG AGG TCT GCG AG (R), PDGFRb: GCC TTA CCA CAT CCG CTC (F), TCA CAC TCT TCC GTC ACA TTG C (R) and GAPDH: GAT TCC ACC CAT GGC AAA TTC C (F),CAC GTT GGC AGT GGG GAC (R) (Integrated DNA Technologies, Coralville, IA, USA). The RT product (0.5 ml) and primers were heated at 941C for 90 s, followed by 28-34 rounds of amplification (30 s denaturing at 941C, 30 s annealing at 601C and 30 s extension at 721C), followed by a final extension of 10 min at 721C. The RT-PCR product was visualized under UV light after fractionation on a 2% agarose gel.
Immunohistochemistry
In all, 47 paraffin-embedded tumor specimens and 10 normal ovarian specimens from the Cooperative Human Tissue Collection (CHTN) and from the Indiana University Tissue Bank Collection were immunostained using an antibody to the PDGFRa (R&D Systems, Minneapolis, MN, USA) at a concentration of 20 mg/ml, and an antibody to PDGF AB (25 mg/ml, Upstate, Waltham, MA, USA). Secondary labeling was based on the avidin/biotin system (Dako, LSAB2 kit). Slides were stained with 3-3 0 -diaminobenzidine (DAB) and counterstained with hematoxylin. Negative controls were run in parallel, with omission of the primary antibody. Staining was graded from 0 (no staining) to 3 þ (strong staining) by a board-certified pathologist. Immunoreactivity was recorded only if noted in more than 15-20% of tumor cells. The Institutional Review Board approved the use of human tissue specimens (protocol# 0301-62).
PDGF AA and BB ELISA In total, 54 samples of ascites fluid from patients with histologically documented ovarian cancer and eight samples of ascites fluid from patients with noncancerous conditions (inflammatory pleural or ascitic fluid) were included in this analysis (UCLA and IUCC Tissue Bank, protocol collection approved by the Institutional Review Board, protocol #0409-02). After collection, samples were centrifuged to remove cellular debris, aliquoted and stored at À801C until use. 96-well plates were coated with capture antibody during an overnight incubation at room temperature (anti-PDGF AA, 1 mg/ml and anti-PDGF BB, 1 mg/ml, Peprotech). After blocking with BSA, samples were incubated at room temperature for 2 h. Biotinylated anti-PDGF AA (1 mg/ml) and BB (0.25 mg/ml) antibodies (Peprotech) were used for detection. After a 30-min incubation with avidin peroxidase (1:2000, Sigma), the reaction was developed with 2,2 0 -azino-bis-3-ethylbenzothiazoline 6-sulfonic acid (Sigma) and quantified at 405 nM in an ELISA plate reader (SpectraMax190, Molecular Devices). Standardization of the ELISA procedure was performed with serial dilutions of recombinant PDGF AA and BB (Peprotech). The lowest level of detection was 150 pg/ ml for PDGF AA and 50 pg/ml for PDGF BB. All samples were quantified in duplicate and, for most specimens (depending on availability), repeat readings from a separate experiment were obtained. SKOV3, OV90 and CaOv3 cells (ATCC, Manassas, VA, USA) were grown according to the instructions provided by the ATCC. CSOC848 and CSOC908 (a generous gift from Cedars Sinai Ovarian Cancer repository, Dr RL Baldwin) are primary ovarian cultures established from tumors and HOSE is a primary culture derived from normal ovarian epithelium, as described previously (Karlan et al., 1995; Ismail et al., 2000) . The immortalized ovarian cell lines C272/hTert/E7 and H281/ hTert/E7 were obtained by transducing the catalytic subunit of human telomerase and the papilloma virus subunit E7 into primary cultures, as described (Gillan et al., 2002) . OVCA cells are primary cultures established from ascites fluid from patients with platinum-resistant EOC, by re-suspending the mixture of cells pelleted from peritoneal fluid in growth media. Nonadherent cells are washed off after 24 h. The cultures from peritoneal fluid are not pure and contain mesothelial elements. Microscopic examination and staining for cytokeratins and vimentin confirm that at least 90% of cells are of epithelial origin. Like other primary ovarian cells, these cultures express cytokeratin AE1/AE3 and vimentin (Karlan et al., 1995, see Supplementary Information) . Primary and immortalized ovarian cells were grown at 371C, under 4% CO 2 in growth media containing 1:1 MCDB 105 media (Sigma, St Louis, MO, USA) and M199 media (Cellgro, Herndon, VA, USA) supplemented with 10% FCS and 1% penicillin/streptomycin. All other cells were grown in the presence of 10% FBS, unless otherwise specified, and were harvested during the log growth phase, at 80-90% confluence. The Indiana University institutional review board approved the establishment and use of primary cells from consenting donors (IRB#0211-50).
Cell lines
si-RNA C272hTert/E7 cells in the logarithmic growth phase were treated with siRNA for the PDGFRa (Smart Pool, Dharmacon) or control siRNA (Dharmacon) using the Fugene 6 transfection reagent (Roche). 15-20% plasmid transfection efficiency was usually achieved.
Cell stimulation
After 48 h of serum starvation, cells were stimulated with PDGF AA, PDGF BB, conditioned media or ascites fluid. The optimal concentration for PDGF AA and BB was determined by titration. Serum-free conditioned medium, containing 0.1% BSA, was collected and centrifuged to remove cellular debris. Neutralizing anti-PDGF AB antibody (Upstate Technologies) was incubated with conditioned media or with PDGF AA or BB at room temperature for 1 h before use for cell stimulation. PDGFRa neutralizing antibody 3G3 was a gift from Dr N Loizos (Imclone). The antibody is fully humanized, specifically recognizes PDGFRa (Kd 40 pM) and blocks PDGF AA and BB receptor binding (Loizos et al., 2005) . Cells were harvested within 30 min of stimulation, unless otherwise specified.
Cell proliferation
An ELISA colorimetric method based on measurement of BRDU incorporation during DNA synthesis (Roche Diagnostics, Penzberg, Germany) assessed cell proliferation. In brief, after treatment, cells were incubated with BRDU (10 mM) for 3 h. After fixation and denaturation, cells were treated with peroxidase-labeled anti-BRDU antibody for 90 min and the colorimetric reaction was developed with a tetramethylbenzidine-based substrate. The reaction product was measured in an ELISA plate reader at an emission wavelength of 370 nM. All assays were performed in triplicate and data are presented as mean7standard deviation.
Immunoblotting Actively growing cells were lysed into RIPA buffer containing leupeptin (1 mg/ml), aprotinin (1 mg/ml), PMSF (400 mM) and Na 3 VO 4 (1 mM). Cell lysates were sonicated and incubated on ice for 30 min. Cellular debris was removed by centrifugation for 15 min. Equal amounts of protein from the supernatants were separated by SDS-PAGE, transferred to a nitrocellulose membrane and treated with a primary antibody (anti-phospho Akt rabbit antibody (Cell Signaling, 1:1000 dilution), total anti-Akt antibody (Cell Signaling, 1:1000 dilution), anti-phospho-MAPK 1, 2 antibody (Cell Signaling, 1:1000), anti-phospho PDGFRa antibody (Santa Cruz, CA, USA), anti-PDGFRa antibody (Cell Signaling, 1:1000), antiPDGFRb (Santa Cruz, 1:250), anti-c-kit (Oncogene, 1:250) and anti-GAPDH (Santa Cruz 1:10 000)) during an overnight incubation at 41C. After incubation with the corresponding HRP-labeled secondary antibodies, enhanced chemiluminescence was used for protein visualization.
PDGFRa immunoprecipitation
Cells were lysed on ice in a buffer containing 20 mM Hepes (pH 7.4), 50 mM b-glycerophosphate, 2 mM EGTA, 1 mM DTT, 1 mM Na 3 VO 4 , 1% Triton X-100, 10% glycerol, leupeptin (1 mg/ml), aprotinin (1 mg/ml) and PMSF (400 mM), as described previously (Hu et al., 1998) . After 15 min, lysates were centrifuged at 13 000 r.p.m. for 30 min to pellet cellular debris. In all, 500 mg of protein from the supernatant was incubated for 90 min at 41C with 5 mg of anti-PDGFRa polyclonal rabbit antibody (Upstate Technology, Waltham, MA, USA), then with 50 mg of slurry of protein G plusAgarose beads (Oncogene, Boston, MA, USA) for 90 min at 41C. Protein-antibody-bead complexes were centrifuged in a wash buffer containing 0.2% Triton and then boiled for 5 min in 1 Â SDS protein-loading dye. PY20 antibody (Santa Cruz, CA, USA) was used to detect phosphorylated tyrosine residues. As control, an anti-PDGFRa antibody was used for immunoblotting.
Neutralizing antibodies
Neutralizing antibody to PDGF AB was purchased from Upstate Technology and used according to the manufacturer's instructions. The neutralizing antibody to PDGFRa 3G3, a fully human antibody with high affinity for PDGFRa binding was a generous gift from Dr Nick Loizos, ImClone Inc. (Loizos et al., 2005) . Rituximab (Genentech Inc., San Franscisco, CA, USA), a humanized anti-CD20 murine antibody, was used as control.
Statistical analysis
The two-sample Wilcoxon rank-sum test compared IHC immunoreactivity between cancer and normal subgroups. Fisher's exact test evaluated the relationship between PDGFR and PDGF AB expression in ovarian tumor samples. For analysis, the data were dichotomized, 0 and 1 þ values being grouped as negative, and 2-3 þ values as positive. Two-tailed t-test compared the results of cell proliferation assays.
